Costs used in the model (2012 prices)
| Item | Cost (£) | Source |
|---|---|---|
| Costs of RSSO | 2165 | NHS reference costs25 |
| HRT costs (for premenopausal women) | 391 | BNF69 |
| Osteoprotection costs | 441 | BNF,69 NHS reference costs25 |
| Cost of diagnosis and initial treatment of ovarian cancer | 16 044 | NHS reference costs,25 NICE guideline70 |
| Annual cost of ovarian cancer treatment and follow-up: years 1–2 | 639 | NHS reference costs,25 NICE guideline70 |
| Annual cost of ovarian cancer treatment and follow-up: years 3–5 | 274 | NHS reference costs,25 NICE guideline70 |
| Ovarian cancer terminal care costs | 15 414 | National Audit Office71 |
| Costs for breast cancer screening | 330 | Robertson,72 NHS reference cost25 |
| Breast cancer treatment costs | 16 537 | NHS reference costs,25 NICE guideline advanced breast cancer,41 NICE guidelines early and locally advanced breast cancer73 |
| Yearly cost of breast cancer follow-up and adjuvant treatment if any (eg, tamoxifen): years 1–5 | 2003 | BNF,69 Robertson,72 NHS reference costs25 NICE guidelines early and locally advanced breast cancer73 NICE guideline advanced breast cancer41 National costing report. Implementing NICE guidance 200939 |
| Fatal CHD costs | 3277 | NHS reference costs25 71 |
All costs were varied by ±30% in one-way sensitivity analysis.
Explanation of costs: see online supplementary table S1 for a detailed explanation of costs in the model.
BNF, British National Formulary; CHD, coronary heart disease; HRT, hormone replacement therapy; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; RRSO, risk-reducing salpingo-oophorectomy.